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Abstract 
Onset of obesity-induced type 2 diabetes occurs when pancreatic ,8-cells fail to meet 
the increased insulin demand caused by insulin resistance. Changes in adipose tissue 
function in obesity results in abnormal deposition of lipids in non-adipose tissues 
including pancreatic islets. Chronic exposure to fatty acid is lipotoxic to the ,8-cells, 
blunting glucose-stimulated insulin secretion. Peroxisome proliferator activated 
receptor-c5 (PPARc5) belongs to the family of PP AR nuclear transcription factors, key 
regulators of lipid metabolism. In pancreatic ,8-cells PP ARc5 has been shown to 
regulate genes involved in mitochondrial handling of fatty acids causing up regulation 
of genes involved in mitochondrial fatty acid oxidation. In addition to its role in lipid 
metabolism, an in-vivo model of ,8-cell specific PPARc5 knockout demonstrated a role 
for PP ARc5 in regulating the cellular machinery involved in secretion of insulin 
granules. Removal of PPARc5 from the ,8-cell enhanced second phase insulin secretion 
due to disassembly of filamentous actin, allowing uninhibited insulin granule 
secretion. The goal of my project was to determine if the pro-oxidative potential of 
PP ARc5 could protect pancreatic ,8-cells from lipotoxicity induced by obesity or if 
PP ARc5' s role in insulin secretion would prevent beneficial effects on fi-cell function. 
Utilizing an adeno-associated virus ( dsAA V8), we induced overexpression of PPARc5 
specifically in pancreatic ft-cells of adult C57Bl6 mice fed a chow or high-fat diet. 
We observed that overexpression of PP ARc5 in pancreatic ft-cells , significantly 
impairs glucose-stimulated insulin secretion in both lean and obese mice supporting a 
role for PP ARc5 in the regulation of insulin secretory mechanisms. Characterization of 
filamentous actin, expression and activity of SNARE proteins in ff-cells 
overexpressing PP ARJ will help to elucidate the mechanism by which PP ARJ results 
insulin granule exocytosis. 
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Fig 1.0: Mechanism of biphasic glucose-stimulated insulin secretion. A. Glucose is 
transported into the p cell by glucose transporters, and then metabolized, leading to 
increases in the ATP concentration ( or ATP/ ADP ratio), closure of ATP-sensitive K + 
(KATP) channels, depolarization of the P-cell membrane, and opening of the voltage-
dependent Ca2+ channels (VDCCs ), thereby allowing Ca2+ influx. The resultant rise 
in intracellular Ca2+ concentration (Ca2+) in the P-cell triggers insulin secretion in 
triggering phase and amplifying phase. B. First phase of insulin secretion results from 
a RRP (readily reserve pool) composed of docked insulin granules, the second phase 
of insulin secretion results from a RP (reserve pool) associated with the cortical actin 
network (Kalwat and Thurmond 2013). 
Fig 2.0: dsAAV8-RIP-PPAR8 plasmid map with MluI restriction sites. 
Fig 2.1: Immunohistochemical analysis of pancreatic sections from untreated mice 
revealed that the IHC technique employed with antibodies to insulin and eGFP 
produce expected results when performed on mouse islets. 
Fig 2.2: A Immunohistochemical analysis revealed that infection of mice with 
dsAAV8-RIP-eGFP induces expression of eGFP in P-cells of P-eGFP-chow and P-
eGFP-HFD mice but not in P-cells of untreated control mice. B The percentage of 
eGFP immunoreactive area in total insulin positive area of islets from P-eGFP-chow 
and P-eGFP-HFD mice is 74% and 24% respectively. Abbreviations: dsAAV8, double 
stranded adeno-associated virus serotype 8; RIP, rat insulin promotor; eGFP enhanced 
green fluorescent protein. Images taken at 20x magnification. Scale bar 50µm. 
Fig 2.3: A. Western analysis of eGFP protein expression in non-pancreatic tissues. 
Non-specific binding of the eGFP primary Ab was observed in liver, skeletal muscle 
and gWAT tissue in both P-eGFP-chow mice and P-PPARJ-chow mice. 30µg of 
protein per sample was loaded and run (see methods); except for gWAT in which 6.3 
µg was used. a-tubulin immunoreactivity was utilized as a loading control. 
Abbreviations: dsAAV8, double stranded adeno-associated virus serotype 8; RIP, rat 
insulin promotor; eGFP, enhanced green fluorescent protein; -C, negative control 
(non-transfected MIN6 cells); +C. positive control, eGFP transfected MIN6 cells; 
gWAT, gonadal white adipose tissue. B. Immunohistochemical analysis of eGFP 
expression in non-pancreatic tissues. Staining revealed no eGFP expression in liver, 
skeletal muscle or gWAT tissue sections from P-eGFP-chow mice or P-PPARJ-chow 
mice. Images taken at 20x magnification. Scale bar 50µm 
Fig 2.4: Immunohistochemical analysis to detect PPARJ overexpression in pancreatic 
P-cells. Immunofluorescent staining revealed increased PPARJ immunoreactivity in 
pancreatic P-cells of mice infected with dsAAV8-RIP-PPARJ (fi-PPARJ-chow and P-
PPARJ-HFD mice). PPAR8 immunofluorescence colocalized with nuclear staining 
(DAPI) in insulin positive cells as indicated by the red (PPARJ), blue (nuclei) and 
V 
green (insulin) overlay. Abbreviations: dsAAV8 - double stranded adenoassociated 
virus serotype 8; RIP - rat insulin promotor; PPAR(5 -Peroxisome proliferator 
activated receptor. Images taken at 20x and lOOx magnification. Scale bar 50µm and 
lOµm. 
Fig 3.0: Comparison of lean and obese mice overexpressed eGFP in pancreatic p 
cells. Body weight A, 4 hr fasted blood glucose B, Insulin sensitivity C, at (Ci) 
Baseline, (Cii) 2-months post-infection, (Ciii) 3-months post-infections was observed 
(1 U insulin/kg). Glucose tolerance D at (Di) Baseline, (Dii) 2-months post-infection, 
(Diii) 3-months post-infections (2g D-glucose/kg) E, P-eGFP-HFD mic exhibit higher 
glucose stimulated insulin secretion compared to P-eGFP-chow mice in response to a 
glucose challenge (2g/kg) (Ei) 2-months post-infection and (Eii) 3-months post-
infections. F, Fasted (16 h) and fed insulin levels in P-eGFP-chow mice and P-eGFP-
HFD mice. 
Fig 3.1: Effect of pancreatic P-cell-specific PPAR8 overexpression in lean mice: Body 
weight A, 4 hr fasted blood glucose B, Insulin sensitivity C, at (Ci) Baseline, (Cii) 2-
months post-infection, (Ciii) 3-months post-infections was observed (1 U insulin/kg). 
Glucose tolerance D at (Di) Baseline, (Dii) 2-months post-infection, (Diii) 3-months 
post-infections (2g D-glucose/kg) and E P-PPAR8-chow mic exhibit lower glucose 
stimulated insulin secretion compared to P-eGFP-chow control mice in response to a 
glucose challenge (2g/kg) (Ei) 2-months post-infection and (Eii) 3-months post-
infections. F Fasted (16 h) and fed insulin levels in P-PPAR8-chow mice and P-eGFP-
chow mice. 
Fig 3.2: Effect of pancreatic P-cell-specific PPAR8 overexpression in diet induced 
obese mice: Body weight A, 4 hr fasted blood glucose B, Insulin sensitivity C, at (Ci) 
Baseline, (Cii) 2-months post-infection, (Ciii) 3-months post-infections was observed 
(1 U insulin/kg) and Glucose tolerance (D) at (Di) Baseline, (Dii) 2-months post-
infection, (Diii) 3-months post-infections (2g D-glucose/kg). E P-PPAR8-HFD mic 
exhibit lower glucose stimulated insulin secretion compared to P-eGFP-HFD control 
mice in response to a glucose challenge (2g/kg) (Ei) 2-months post-infection and, 
(Eii) 3-months post-infections. F Fasted (16 h) and fed insulin levels in P-PPAR8-
HFD mice and P-eGFP-HFD mice. 
Fig 4. 0 Immunohistochemical analysis to visualize F-actin staining in pancreatic P-
c ells of saline infected mice. A. Phalloidin dye treated pancreatic section of saline 
infected mice showed no F-actin staining in P-cells. Control of the technique i.e 
pancreatic section of saline injected mice with no Phalloidin dye showed no 
imrnunofluorescence. B. Pancreatic sections treated with 0.5% triton-x 100 for 10 and 
30 minutes also showed no immunofluorescence in P-cells. 
Fig 5.0: Overexpression of PPAR8 in INS-1 cells and expression of insulin exocytosis 
mediators: Overexpression of INS-1 cells with PPARcS and treatment with palmitate 
downregulate expression of Snap23mRNA while no change in expression of other 
mediators. Abbreviations: PPARcS - peroxisome proliferator-activated receptor alpha; 
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INS- I rat insulinoma cell line; eGFP - enhanced green fluorescent protein, V AMP2 -
vesicle associated membrane protein 2, CDC42 - cell division control protein 42, 
PAK 1- p2 l-activated protein kinase 1, SNAP23 - Synaptosomal-associated protein 
23, and SNAP25 -Synaptosomal-associated protein 25. 
Fig 6.0 Pathways impinging specifically on glucose-mediated F-actin remodeling in 
the ~ cell and PPAR8 involvement in the pathway by highlighting the areas of future 
direction based on already known role of PPAR8 and key finding of my study 
(Kalwat and Thurmond 2013) . 
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CHAPTER! 
Lipotoxicity - A bridge between Obesity and Type 2 Diabetes. 
1.1 General introduction to Diabetes 
Diabetes is no longer an epidemic that can be ignored. Diabetes figures are increasing 
rapidly and it carries a high burden of mortality and morbidity. According to an estimate 
by the International Diabetes Federation, 415 million people were living with diabetes in 
2015; by 2040 this will rise to 642 million. Diabetes was responsible for 5 million deaths 
in 2015, which means every 6 seconds a person died from diabetes. Looking at these 
alarming figures it is imperative that researchers strive to discover new therapeutic 
strategies to overcome this disease. Different types of diabetes result from heterogeneous 
etiologies with the common clinical presentation of hyperglycemia. Underlying causes of 
hyperglycemia are either insulin deficiency or impaired insulin action or both (Monsalve, 
Pyarasani et al. 2013). Type 2 Diabetes (T2D) is a polygenic disease characterized by 
insulin resistance and inadequate insulin production (Iglesias, Barg et al. 2012). T2D is 
the most prevalent type of diabetes, accounting for 90% of cases worldwide (Nolan, 
O'Halloran et al. 2006). In the long term, T2D results in life time suffering for patients 
due to its associated complications including diabetic nephropathy, retinopathy, damage 
to peripheral nerves leading to amputation of extremities and heart failure (Tan, Chong et 
al. 2012). T2D associated complications carries a crushing economic strain on health care 
system, due to the high costs associated with management of diabetic complications 
(Zimmet 2003) 
1.2 General introduction to lipotoxicity 
The Obesity epidemic is rising year-over-year with recent worldwide figures estimated 
at 1.4 billion (O'Neill and O'Driscoll 2015). Sedentary lifestyles that include increased 
nutrient consumption along with decreased physical activity have significantly increased 
rates of obesity (Prentki and Nolan 2006). Obesity is the major pre-requisite of the 
Metabolic Syndrome, which is a set of combined risk factors of central obesity, insulin 
resistance and dyslipidemia that together increase prevalence of T2D (O'Neill and 
O'Driscoll 2015). In addition to T2D, obesity is associated with numerous diseases 
including and not limited to cardiovascular disease, cancer, osteoarthritis, and non-
alcoholic fatty liver disease (Bray 1985; Kahn, Haffner et al. 2006). Obesity is the main 
risk factor for the global pandemic of T2D as 80% of people diagnosed with diabetes are 
overweight or obese (Smyth and Heron 2006). The pathophysiological mechanisms 
underlying this association are not well understood. One of the prevailing hypotheses 
linking obesity and T2D is lipotoxicity, where limitations of adipose tissue expandability 
result in the inability of adipose tissue to accommodate excessive lipids in the obese state, 
leading to ectopic deposition of lipids in non-adipose tissues (Ahima 2006; Chavez and 
Summers 2010). 
Adipose tissues are complex organs composed of vascular tissue, immune cells and 
adipocytes which are the main cell type for triglyceride storage (Yaney and Corkey 
2003). In the non-obese state, adipocytes maintain lipid homeostasis by storing lipid as 
triglyceride in times of nutrient excess, and utilizing lipid via the lipolysis of triglycerides 
in times of fasting (Gray and Vidal-Puig 2007). Healthy adipocytes undergo hypertrophy 
and hyperplasia to store lipids in times of ovemutrition (Andrew, S. 2011). However, it 
has been suggested that adipocytes cannot expand infinitely, so with chronic over-
nutrition there is a limit to the storage capacity of adipose tissue and excessive lipid starts 
to leak out from adipocytes into the circulation (Andrew, S. 2011 ). This "spillover" of 
lipids results in elevated circulating levels of fatty acid and triglyceride as well as 
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abnormal accumulation of lipids in non-adipose tissues such as skeletal muscle, liver, 
heart and pancreas (Eldor and Raz 2006), a phenomenon known as lipotoxicity. 
The term lipotoxicity has been used to describe abnormal deposition of lipid species in 
non-adipose tissues that leads to impaired cellular function and apoptosis (Unger and 
Scherer 2010). Abnormal deposition of lipid moieties occur either by increased uptake of 
fatty acids (F As), increased synthesis within the tissue involved, or reduced disposal by 
fatty acid oxidation (Kahn, Haffner et al. 2006; van Herpen and Schrauwen-Hinderling 
2008). During period of over nutrition, fatty acids are ineffectively oxidized, resulting in 
increased concentrations of lipid intermediates such as diacylglycerol (DAG), ceramides 
and acyl-CoA (van Herpen and Schrauwen-Hinderling 2008). Increased production of 
deleterious lipid species such as ceramides and diacylglycerols (Kahn et al. 2006) trigger 
apoptosis, a process known as lipoapoptosis (Kusminski, Shetty et al. 2009) as well as 
induce oxidative stress in cells resulting in impairments in endoplasmic reticulum (ER) 
and mitochondrial function (Kusminski, Shetty et al. 2009; Schrauwen, Schrauwen-
Hinderling et al. 2010). 
More specifically, accumulation of intermediate toxic lipid species m non-adipose 
tissues, such as skeletal muscle or liver leads to impairments in insulin sensitivity 
(Chavez and Summers 2010). Interestingly, another site of lipid accumulation is the 
pancreas, where ectopic lipid deposition is associated with pancreatic ~-cell dysfunction 
and ~-cell failure, a proposed mechanism of obesity induced T2D (Prentki and Nolan 
2006). 
To understand the mechanism of obesity-mediated insulin resistance and impairment in 
insulin secretion it ' s better to first review the mechanisms of glucose stimulated insulin 
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secretion. 
The molecular mechanism of glucose stimulated insulin secretion is well explained in 
the published literature illustrated by Fig 1.0: A and B. 
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Fig 1.0: Mechanism of biphasic glucose-stimulated insulin secretion. A. Glucose is 
transported into the p cell by glucose transporters, and then metabolized, leading to 
increases in the ATP concentration (or ATP/ADP ratio), closure of ATP-sensitive K+ 
(KATP) channels, depolarization of the P-cell membrane, and opening of the voltage-
dependent Ca2+ channels (VDCCs), thereby allowing Ca2+ influx. The resultant rise 
in intracellular Ca2+ concentration (Ca2+) in the P-cell triggers insulin secretion in 
triggering phase and amplifying phase. B. First phase of insulin secretion results from 
a RRP (readily reserve pool) composed of docked insulin granules, the second phase 
of insulin secretion results from a RP (reserve pool) associated with the cortical actin 
network (Recreated from susumu seino et al 2011) 
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In response to increased blood glucose levels, insulin is released from dense core 
pancreatic islet ~-cells in a biphasic manner (Heaslip, Nelson et al. 2014). The first phase 
results in a rapid robust spike of insulin release due to rapid fusion of granules that are 
pre-docked at the plasma membrane. These pre-docked granules are referred as the 
'readily releasable pool' (RRP) (Wang and Thurmond 2009). Second, prolonged release 
of insulin occurs in response to sustained stimulation and requires recruitment of granules 
from the storage pool to the plasma membrane (Heaslip, Nelson et al. 2014). Docking and 
fusion of insulin granules is mediated by a group of proteins termed as soluble N-
ethylmaleimide sensitive factor attachment receptor (SNARE) proteins. SNAREs can be 
classified into two subfamilies, vesicle-SNAREs and target-SNAREs (Rondas, Tomas et 
al. 2011). Target-SNARE proteins, syntaxin 1 (Stxl) and SNAP25 are localized at the 
plasma membrane, whereas the vesicle-SNARE protein V AMP2 is associated to insulin 
secretory granules (Hou and Pessin 2007). Granule exocytosis involves the specific 
binding of the vesicle-associated membrane protein (VAMP), i.e. vesicle-SNARE to 
target-SNARE proteins, composed of SNAP25/23 proteins to form heterotrimeric 
SNARE core complex that facilitates membrane fusion and ultimately insulin release 
(Oh, Kalwat et al. 2012). SNARE protein are involved in both phases of insulin release, 
specifically syntaxin-1 is involved only in first phase while syntaxin-4 is involved in both 
phases on insulin release (Kalwat and Thurmond 2013). 
During second-phase of insulin secretion, recruitment of insulin granules from storage 
pool involves remolding of the filamentous actin (F-actin) cytoskeletal network. F-actin 
remodeling is known to mechanistically couple granule mobilization to the SNARE 
exocytosis machinery to release insulin in transient manner (Kalwat and Thurmond 
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2013). Under basal condition F-actin plays a barrier role hence, restrict insulin granule 
access to the plasma membrane docking and fusion machinery. 
Insulin released from B-cells of the pancreas travels through the blood and binds insulin 
receptors on target tissues in the periphery. Insulin is a peptide hormone that directs lipid 
and glucose anabolic pathways upon insulin receptor activation. 
1.3 Lipotoxicity and fl-cell failure in type 2 diabetes 
T2D is an amalgam of impairments in insulin sensitivity (associated with ectopic 
deposition of toxic lipid moieties in peripheral tissues such as liver, skeletal muscle and 
adipose tissues) and insulin secretion ( associated with direct lipotoxic effects on 
pancreatic B-cell function). Much of the literature is focused on how ectopic lipotoxic 
accumulation contributes to insulin resistance in peripheral tissues, which requires the B-
cell to produce more insulin to maintain normoglycemia. Often this higher insulin 
secretion cannot be sustained and diabetes develops. A predominant theory for B-cell 
failure is B-cell exhaustion via disruption of the insulin secretory pathways due to 
lipotoxic accumulation in the B-cell (Poitout, Briaud et al. 2004; Kahn, Haffner et al. 
2006). Over the last 20 years much research has been focused on causes and cure of 
lipotoxic accumulation specifically in pancreatic B-cells. 
Acute and chronic effects of fatty acid (FA) exposure have been well studied in 
pancreatic B-cell. Acute exposure of the pancreatic B-cell to FF A is part of the 
physiological stimulus for normal insulin secretion. (Nolan, Leahy et al. 2006). Short 
term exposure results in accumulation of long-chain acyl-CoA (LC-CoA) (mediator of 
FA) that is a precursor of diacylglycerol and phosphatidic acid leading to activation of 
PKC and ultimately insulin secretion. FF A also bind to the G-protein couple receptor, 
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GPR40, and increase glucose-stimulated insulin secretion in a Ca2+ dependent manner 
(Assimacopoulos-Jeannet 2004). 
Accumulative evidence has shown that chronic FA exposure has detrimental effects on 
P-cell health and will lead to significantly repressed glucose-stimulated insulin secretion. 
The specific mechanism by which ectopic lipid accumulation inhibits insulin secretion 
remains unclear. One central understanding is that chronic elevated lipids result in 
increased FA oxidation that leads to generation of deleterious metabolic intermediates, 
responsible for impaired insulin secretion and ultimately P-cell failure. According to this 
idea, concurrent hyperglycemia and elevated FA results in accumulation of cytosolic 
citrate, a precursor of malonyl-CoA which leads to camitine-palmitoyl-tranferase-1 
inhibition, an enzyme responsible for transport of FA into the mitochondrion. Sustained 
inhibition of camitine-palmitoyl-tranferase-1 results in accumulation of long-chain fatty 
acyl CoAs (LC-CoA); (Prentki and Corkey 1996). LC-CoA accumulation directly affects 
P-cell function, or it serves as a precursor for other lipotoxic moieties such as 
diacylglycerol. Ceramides and diacylglycerol have been shown to induce oxidative stress 
inducing apoptosis of P-cells (van Herpen and Schrauwen-Hinderling 2008) while other 
studies suggest that modulation of gene expression related to insulin secretion and other 
related signalling pathways may be the cause of impaired P-cell function (van Herpen and 
Schrauwen-Hinderling 2008). The lipotoxic hypothesis of obesity-induced T2D suggests 
chronic hyperglycemia and hyperlipidemia due to oversupply of nutrients leads to 
lipotoxic accumulation of cytotoxic lipid species resulting in impaired insulin sensitivity 
(in peripheral tissue) and impaired insulin secretion from P-cells. Together, impairments 
in insulin sensitivity and secretion leads to further exacerbate dyslipidemia in diabetic 
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patients. 
Considering the entire lipotoxic dilemma and disruption in various cell types it would 
be wise to examine the regulators of lipid pathway to alleviate the impairment in insulin 
secretion due to lipotoxicity. One such regulatory element that is known as a lipid sensor 
in the body and plays a primary role in the regulation of lipid metabolism is a family of 
nuclear transcription factor known as peroxisome proliferator activated receptor (PP AR); 
(Wang, Lee et al. 2003). 
1.4 Peroxisome proliferator activated receptors: master regulators of lipid 
metabolism 
Peroxisome proliferator activator receptors (PP ARs) are ligand-activated transcription 
factors that play key roles in lipid and glucose metabolism, and overall energy 
homeostasis (Stienstra, Duval et al. 2007). Upon fatty acid binding to the ligand binding 
domain, the transactivation domain undergoes a conformational change and 
heterodimerizes with the retinoic X receptor to control transcription through binding to 
specific DNA elements (PPREs) within the promoters of target genes (Palmer, Hsu et al. 
1995). PPAR8 (also called PPAR~), along with its two siblings, PPARa and PPARy, 
constitute the PPAR superfamily (Reilly and Lee 2008). PPARa is highly expressed in 
liver and skeletal muscle and its activation induces transcription of genes involved in 
fatty acid oxidation (Evans, Barish et al. 2004). PPARa activation is key to the fasting 
response where pro-oxidative effects are desirable, when exogenous nutrient supplies are 
low. Pro-oxidative effects of PP ARa activation, specifically in ~-cells of obese mice, are 
able to preserve ~-cell function (Hogh, Uy et al. 2013 ). PP ARy 1 and PP ARy2 are 
expressed most highly in adipose tissue and are established as primarily lipogenic and 
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adipogenic transcription factors within the PPAR family (Tontonoz, Hu et al. 1995). 
PP ARy activation occurs in the fed state, facilitating disposal of lipids in adipose tissues 
(Savage, Petersen et al. 2005). Compared to PPARa and PPARy, PPAR8 is expressed all 
over the body and has an important function in skin, gut, placenta, liver, adipose tissue, 
skeletal and heart muscle and macrophages (Ravnskjaer, Frigerio et al. 2010). Many 
cellular and animal models revealed that PP AR8 plays a crucial role in fatty acid 
metabolism in several tissues as well as in inflammation (Luquet, Lopez-Soriano et al. 
2004). 
In recent years PP AR8 has emerged as an attractive target for metabolic syndrome and 
T2D due to its ability to improve dyslipidemia and insulin sensitivity by PP AR8 
activation (Luquet, Lopez-Soriano et al. 2004; Barish, Narkar et al. 2006). PPAR8 is 
highly expressed in muscle tissue, an important site for insulin action. Tanaka et al. 2003 
showed that PP AR8 activation is a key target for the treatment of diabetes and obesity 
through increases in fatty acid oxidation and improved insulin sensitivity, as well as 
marked reduction in lipid droplets in skeletal muscles (Tanaka, Yamamoto et al. 2003). 
In adipose tissue, PP AR8 has been shown to play an important role in regulating 
dyslipidemia and lipotoxicity through P-oxidation. Targeted activation of PP AR8 in 
adipose tissue specifically induces expression of genes that regulate fatty acid oxidation 
and energy dissipation including camitine palmitoyltransferase 1 (CPTl), acyl-CoA 
oxidase (AOX) and long chain acyl-CoA dehydrogenase (LCAD), and energy dissipation 
gene, including uncoupling protein 1 (UCPl) and UCP3 (Wang, Lee et al. 2003; Reilly 
and Lee 2008). 
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PPARo also induces metabolically beneficial effects through its function in liver 
pathways. PP ARo activation in the liver lowered glucose output due to increased flux of 
glucose into the pentose phosphate shunt resulting in an enhancement of fatty acid 
synthesis (Lee, Olson et al. 2006). PPARo has also been shown to induce improvement in 
serum cholesterol level due to the increased expression of the ATP-binding cassette 
transporter 1 (ABCAl) (van der Veen, Kruit et al. 2005) a cholesterol transport protein, 
and decreased cholesterol absorption in the intestines due to reduced expression of the 
cholesterol absorption protein Niemann-Pick Cl-like 1 (Npclll) in the intestine (van der 
Veen, Kruit et al. 2005). 
Taken together these studies suggest PP ARo may be a prom1smg treatment for 
symptoms associated with T2D and the metabolic syndrome. 
1.5 Peroxisome proliferator activated receptors o in pancreatic f3-cell. 
PP ARo is the most highly expressed member of the PP AR family m P-cells 
(Ravnskjaer, Frigerio et al. 2010). In vitro studies investigating the role of PPARo in a 
pancreatic P-cell line (HIT-15 cells) have suggested that PP ARo activation causes an 
upregulation of genes involved in mitochondrial fatty acid oxidation and helps to 
alleviate palmitate-induced impairment on glucose-stimulated insulin secretion (Wan, 
Jiang et al. 2010). Increased fatty acid oxidation was associated with upregulation of 
uncoupling protein 2 (UCP2), long chain acyl-CoA dehydrogenase (LCAD), pyruvate 
dehydrogenase kinase 4 (PDK4) and camitine palmitoyl transferase 1 (CPTl). Further 
studies examining the role of PP ARo also showed a protective role of PP ARo in 
conditions of lipotoxicity (Ravnskjaer, Frigerio et al. 2010). In addition to its role in lipid 
metabolism in the P-cell, a recent in vivo study characterizing the phenotype of a P-cell 
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specific PP AR8 knockout model suggests a role of PP AR8 in the regulation of cellular 
machinery involved in secretion of insulin granules (Iglesias, Barg et al. 2012). The 
authors reported a broad repressive role of PP AR8 in insulin secretion, removal of 
PPAR8 from the P-cell causes enhanced second phase insulin secretion associated with 
increased disassembly of filamentous actin, allowing easy access of insulin granules to 
the plasma membrane (Iglesias, Barg et al. 2012). 
The primary goal of this study will be to further characterize the role of PP AR8 on P-
cell, a cell type where the role of PP AR8 has still not been fully elucidated. 
1.6 Hypothesis and Study Aims. 
Overexpression of PP AR8 specifically m pancreatic P-cell of mice will induce 
oxidative gene expression and increase oxidative metabolism in pancreatic P-cells. In 
obesity, when islets are exposed to lipotoxic lipid accumulation, overexpression of 
PP AR8 will improve islet function and whole animal carbohydrate metabolism. To test 
this hypothesis, PP AR8 will be overexpressed specifically in pancreatic P-cells of 
C57Bl6 mice fed a regular chow diet or mice fed on high fat diet for 16 weeks and 
changes in carbohydrate metabolism ( chapter 3 focus) will be measured after verifying P-
cell-specific overexpression of PP AR8 ( chapter 2 focus). 
1. 7 Significance of the study. 
If P-cell PP AR8 overexpression enhances oxidative metabolism and reduces lipid 
accumulation within the pancreatic P-cell, without interfering with P-cell function, it 
could potentially delay or prevent the onset of obesity-induced diabetes. Furthermore, 
PP AR8 agonism could serve as a potential therapeutic strategy to preserve P-cell function 
in the lipotoxic condition of obesity. Results of this ;n vivo study, evaluating the potential 
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protective role of PPAR8 in lipotoxic condition, will set the ground work for future 
studies considering PP AR8 activation as a new therapeutic target for the treatment of 
T2D and the metabolic syndrome. Additionally, it would be beneficial to understand the 
tissue-specific role of PP AR8 in the pancreatic P-cell. 
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CHAPTER2 
Optimization of dsAA V-8 - A tool used to P-cell specific overexpression of 
PPARo 
2.1 Introduction 
To conduct the aforementioned research aim, to further uncover the role of PPARJ in 
P-cell function, we developed a transgenic model that overexpresses PP ARJ specifically 
in pancreatic P-cells. Transgenic or genetically modified mouse models have proven to be 
powerful tools for the study of gene function; specifically, they provide in vivo models 
that can be studied to enhance our scientific understanding of underlying molecular 
mechanisms involved in human disease through mechanistic studies (Lin 2008). 
Transgenics includes the addition of foreign genetic information into animals 
(overexpressing a gene of interest) and specific inhibition (knocking out) of endogenous 
gene expression (Houdebine 2009). 
Generation of transgenic mice that express proteins of interest specifically in pancreatic 
P-cells have been challenging to develop because the pancreatic islets are difficult to 
target. The pancreas itself lies deep inside the abdominal cavity and islets of Langerhans 
are scattered throughout the exocrine portion of the pancreas (Coppieters, Roep et al. 
2010). The human genome contains a single copy of the insulin gene, whereas two 
insulin genes are found in rat and mouse (Ins] and Ins2) (Odagiri, Wang et al. 1996). 
Each gene has a different expression profile: Ins I expression is restricted to pancreatic f3-
cells, where it contributes to insulin secretion (Hay and Docherty 2006), whereas, Ins2 is 
the ancestral gene and is expressed in thymus in addition to pancreas (Hay and Docherty 
2006; Martin-Pagola, Pileggi et al. 2009). The DNA sequence that control P-cell specific 
expression are located upstream of the transcription initiation site in the promoter region 
of the gene (Whelan, Poon et al. 1989). Tissue-specific promoter such as the mouse 
insulin promoter (MIP) and rat insulin promoter (RIP) have been used to direct 
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expression specifically in pancreatic P-cell of transgenic mouse models (Gannon, Shiota 
et al. 2000). For example, Hara et al. 2003 generated transgenic mice that express green 
fluorescent protein specifically in pancreatic P-cells ( eGFP) under the control of the 
mouse insulin I gene promoter (MIP). MIP-GFP mice had normal islet architecture with 
indistinguishable insulin content and glucose tolerance as compared to control mice 
(Hara, Wang et al. 2003). 
Despite the above success of expressing eGFP in pancreatic P-cells, several models 
using the RIP promoter to drive expression of transgenes in rat or mice have revealed 
activity of the RIP in brain tissue. Most of this work has been demonstrated in ere-
transgenic mice, used for conditional knockout of genes using the Cre/loxP system for 
animal transgenics that allows knockout of a gene of interest at a specific developmental 
stage or in a tissue-specific manner (Nagy 2000). RIP2-Cre transgenic mice lines were 
generated to target gene knockout to the P-cells of the pancreas. However, numerous 
studies suggest that Cre mice are not specific to pancreatic P-cells and also induce a low 
level of gene knockout in certain regions of the brain, including discrete neuronal 
populations in the hypothalamus and forebrain (Gannon, Shiota et al. 2000; Choudhury, 
Heffron et al. 2005; Gong, Fan et al. 2015). 
Transgenic gene expression driven by the RIP is induced as early as embryonic day 
13.5 (Hara, Wang et al. 2003), inducing overexpression of the gene of interest before 
birth, from E13.5 (Hara, Wang et al. 2003). Thus caution needs to be exercised when 
using RIP2-Cre mice, as RIP2 directs expression of the gene of interest during 
embryogenesis in insulin producing cells of the foregut and neural tissue (Gannon, Shiota 
et al. 2000). To alleviate the concerns of embryonic expression with the RIP, and further 
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restrict RIP activity to adult ~-cells, the RIP-Cre Estrogen receptor (ER) mouse strain was 
developed, whereby the insulin promoter drives the expression of Cre recombinase when 
mice are treated with an estrogen receptor agonist, tamoxifen (Dor, Brown et al. 2004). 
This system has been shown to be challenging to work with, as there are technical 
difficulties associated with tamoxifen dosing and the extent of recombination that occurs 
for example between young and old mice (Johnson 2014). 
All of this information was considered when deciding the most appropriate mouse 
model for implementing in vivo overexpression of PP ARs specifically in pancreatic ~-
cells in this study. 
In addition to traditional transgenics that induce recombination of the genetic material 
at the pronuclear stage, another novel approach to induce transgenic overexpression is via 
viral mediated gene delivery. Viruses are naturally efficient at transducing their own 
genetic information into host cells for their own replication. By replacing non-essential 
viral genes with foreign genes of therapeutic interest, recombinant viral vectors can be 
used to transduce the cell type that they would normally infect (Bouard, Alazard-Dany et 
al. 2009). A number of viral systems are developed for use as vector for ex vivo and in 
vivo gene transfer, including retroviruses, adenoviruses, herpes-simplex viruses and 
adeno-associated viruses (Robbins and Ghivizzani 1998). 
One emerging field is the use of adeno-associated viruses as a mode of viral gene 
delivery. Currently, three classification of adeno-associated viruses exist: single stranded 
adeno-associated virus (AAV), recombinant adeno-associated virus (rAAV) and the 
double-stranded adeno-associated virus (dsAAV) (Wang, Peng et al. 2004; Wu, Asokan 
et al. 2006). In addition, nine subtypes (AAVl-9) have been described for which human 
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is the primary host. 
AA V is one of the smallest virus with a non-enveloped icosahedral capsid belonging to 
the Parvovirdiae family. AA Vs also exhibit low immunogenicity, making them an ideal 
and efficient tool for viral-mediated gene delivery without inducing an immune response 
(Gaddy, Riedel et al. 2010). A VV have been used to deliver genes of interest specifically 
to a variety of tissues including pancreatic P-cells. Rehman et al. 2005 showed that 
dsAA V can be used to deliver genes specifically in pancreatic P-cells, if the transgene 
expression is coupled to the MIP. dsAA V vectors allow for more rapid and efficient 
AA V-mediated transgene expression following transduction in intact human and murine 
islets than ssAA Vs because transgene expression is transcriptionally inactive until 
converted into double-stranded ( ds) template in vivo (Rehman, Wang et al. 2005). AA V-
based vectors can infect both dividing and non-dividing cells resulting in long-term 
efficient transgene expression in animal models. Efficiency of AA V infection has been 
improved through the use of certain serotypes of AA V that have different tropisms in 
vivo. Tissue-specific delivery of the AA Vs is dependent on the serotype capsid with 
which it is associated (Inagaki, Fuess et al. 2006). For example, dsAAV vectors packaged 
in AA V2, 6, and 8 capsids infect human islets more efficiently than serotypes 1, 5, and 7 
(Rehman, Wang et al. 2005). 
The mode of delivery also affects transfection efficiency, and it has been demonstrated 
that intravenous, intraperitoneal (IP), or intraductal injection of AA V8, results in efficient 
transduction of islets in vivo. Wang et al. 2006 concluded that viral delivery via 
intraperitoneal injections was as effective as intraductal and intravenous injection when 
the viral dose was increased to 5x10 11 viral/genomes per mouse and this induced long 
20 
term gene expression in pancreatic ~-cells, as expression was observed for four months 
post infection (Wang, Zhu et al. 2006). Additionally, dsAA V8 has profoundly better in 
vivo activity due to the superior capability of AA V8 in crossing the in vivo barriers, such 
as the peritoneal epithelium and vasculature endothelium, to eventually reach the islets 
for infection. 
AA V8 delivery is directed at tissues in the gut; therefore, site-specific delivery to the ~-
cells of the pancreas is enhanced by utilizing tissue specific promoters such as MIP or 
RIP (Wu, Asokan et al. 2006). The MIP, shown to be ~-cell specific using dsAA V vector, 
was effective in limiting eGFP expression exclusively to the pancreatic ~-cells (Wang, 
Zhu et al. 2006). Rehman et al. 2008 demonstrated dsAA V8-MIP-eGFP induced 
expression of eGFP specifically in pancreatic islets in young female mice after 4 x 1011 
viral genomes were delivered by IP injection (Rehman, Trucco et al. 2008). 
Because dsAA V8 increase vascular permeability in endothelial cell lining of blood 
vessels it has been suggested dsAA V8 can cross the blood brain barrier, however, when 
tested with a transgene driven by the MIP or RIP, GFP expression was not detected in 
brain tissue of infected mice indicating that using dsAA V8-MIP or dsAA V8-RIP to target 
pancreatic ~-cells is an effective method for gene delivery without crossing the blood 
brain barrier (Wang, Zhu et al. 2006). 
A control vector is needed to check the efficiency of test vector in vivo and to see 
correct expression from control element after vector transduction in vivo and persistence 
of transgene expression in vivo . To control viral infection Gaddy and colleagues (2010 
have been able to successfully overexpress eGFP within pancreatic fl-cells without 
causing changes in body weight or carbohydrate metabolism utilizing dsAA V8 (Gaddy, 
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Riedel et al. 2010). More recently the Gray lab showed adeno-associated virus (dsAAV8-
RIP-eGFP) specifically targets expression of enhanced green fluorescent protein ( eGFP) 
to pancreatic P-cells in vivo with no expression observed in pancreatic a-cells, pancreatic 
exocrine tissue or hypothalamus (Hogh, Uy et al. 2013). Additionally ,6-cell-specific 
overexpression of eGFP does not affect body weight, fasted blood glucose, glucose 
tolerance or insulin sensitivity in dsAA V8-RIP-eGFP (Hogh, Uy et al. 2013). 
In summary, viral-mediated gene delivery using dsAA V8 and the RIP is a powerful 
tool to induce in vivo overexpression of target genes specifically in pancreatic ,6-cells. 
Additionally, previous studies have shown that dsAAV8-RIP-eGFP can be used as a 
control vector without affecting carbohydrate metabolism. For this study where we wish 
to assess the effect of PP ARJ on P-cell function in response to normal and high fat diet, 
the advantages of dsAA V8 over traditional transgenesis include: 1) The virus expressing 
PPARJ under the control of the RIP promoter will be delivered via ip injection to adult 
mice, localizing expression of PP ARJ specifically to pancreatic P-cells 2) The virus can 
be delivered prior to or after a treatment such as high fat diet, 3) The virus will induce 
stable expression of PP ARJ in both dividing and non-dividing pancreatic P-cells 
throughout the 4 month study required to induce obesity in the high fat treated mice and 
4.) dsAA V8 induces a very low immunogenic response. 
This chapter describes the viral vectors (dsAAV8-RIP-eGFP and dsAAV8-RIP-
pp ARJ) designed to induce expression of eGFP or PP ARJ specifically in pancreatic P-
cells and presents data that validates dsAA VS-mediated induction of PP AR8 
overexpression specifically in pancreatic P-cells to further assess its role in pancreatic P-
cell function in the lean and obese state. 
22 
2.2 MATERIALS AND METHODS 
Design and preparation of dsAA V8-RIP-eGFP construct 
The dsAA V8 transfer vector contained the RIP ( 410 bp) placed upstream of sequence 
encoding the eGFP (720bp) open reading frame, followed by the SV40 polyadenylation 
signal had previously been designed and generated in the Gray lab by other graduate 
students. 
Design and preparation of dsAA V8-RIP-PPARo constructs 
A plasmid ( dsAA V8) containing the PP AR8 gene insert under control of the RIP 
(dsAA V8-RIP-PPAR8, 5931bp) was transformed into XLI-Blue competent E. coli cells 
for cloning. Cells were lysed and plasmid DNA was purified (Plasmid Plus Giga Kit, 
Qiagen, Valencia CA, USA). A restriction enzyme digest was performed using Mlul 
endonuclease (New England Biolabs, Whitby ON, Canada) and plasmid DNA sequenced 
to ensure the plasmid contained the accurate RIP and PP AR8. 
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dsAAVS-RIP-PPARl> sooo -
5,931bp 
Miu/ PPARl> 
Fig 2.0: dsAAV8-RIP-PPARi5 plasmid map with Mlul restriction sites. 
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Double-stranded adeno-associated virus serotype 8. 
For this study dsAAV8 virus was prepared (dsAAV8-RIP-eGFP (5328bp), dsAA V8-RIP-
pp AR8 (5931 bp) from the constructs by Children's Hospital of Philadelphia (CHOP) 
Research Vector Core Services (Philadelphia PA, USA). 
Mice 
All animal studies were approved by the University of Northern British Columbia Animal 
Care and Use Committee (protocol number 2011-21). For this study, 8 week-old, male, 
C57Bl6 mice were purchased from Charles River Laboratories (Wilmington MA, USA). 
Mice were maintained on a 12 hr light/dark cycle and received standard rodent chow diet 
(Rodent LabDiet, 5001, Leduc AB, Canada) ad libitum unless otherwise stated. Mice 
acclimatized in the animal facility for 1 week prior to experimental procedures. Body 
weight, 4 hr fasted blood glucose (OneTouch Ultra, Lifescan, Burnaby BC, Canada), 
overnight and random fed insulin level, oral glucose tolerance test (OGTT) and insulin 
tolerance test (ITT) were performed prior to viral injections to assess baseline carbohydrate 
metabolism (described in the methodology section of Chapter 3). 
Pancreatic f3-cell specific overexpression of eGFP and PPAR <> in mice 
At 12-weeks of age, C57Bl6 mice were infected with dsAA V8-RIP-PPAR8 virus or 
dsAA V8-RIP-eGFP virus (5x10 12 viral genomes/mice) via intraperitoneal (ip) injection. 
Two days postinfection, mice were fed either a normal chow diet (Rodent LabDiet, 5001; 
LabDiet Inc., Leduc, AB, Canada) or high fat diet (D12451; Research Diets, New 
Brunswick, NJ, USA) for 13 weeks to induce obesity. Four groups of mice were generated 
(n=8) per group: ,6-eGFP-chow mice, .B-PPAR8-chow mice, ,6-eGFP-HFD mice, .B-PPAR8-
HFD mice. After 16wks mice were sacrificed by an overdose of isoflurane anaesthetic and 
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tissues were collected. 
Immunohistochemistry 
Whole mice pancreas were weighed and fixed in 4% paraformaldehyde, embedded in 
paraffin and sectioned (5µm); n=5 per group (Wax-it Histology Services; Vancouver BC, 
Canada). All sections were de-paraffinized in xylene, rehydrated in ethanol (100%, 95%, 
and 70%) and rinsed with lxPBS. Sections were incubated overnight with primary antibody 
as follows: polyclonal rabbit anti-eGFP 1 :500; dilution; Al 1122; Invitrogen Molecular 
Probes); polyclonal guinea pig anti-insulin (1:1000; dilution; 4011-0lF; Millipore) and 
polyclonal rabbit anti-PPARJ (1: 100; dilution; Ab8937; Abeam). Appropriate secondary 
whole (heavy and light chain) antibodies conjugated to Alexafluor 488 (1: 1000; dilution; 
A21206 and A21202 or 594 Al 1076 and A11032; Invitrogen Molecular Probes) were used 
to detect primary antibody immunoreactivity. All samples were visualized using a 
fluorescent light microscope (Olympus BX61) and images analyzed using Cell Sens 
Software (Olympus, Markham ON, Canada). 
Western blot analysis 
Liver, heart, gonad, kidney, gonadal white adipose tissue and skeletal muscle 
samples were collected and flash frozen. Protein was extracted using RIP A buffer 
(Thermo Scientific, Rockford IL, USA) and quantified using a bicinchoninic acid 
assay (BCA assay) (Thermo Scientific, Rockford IL, USA). Protein for all tissues 
(30µg, except gWAT, 6.3µg) was separated on a 12% SDS-PAGE gel and transferred 
to a PVDF membrane (Millipore, Billerica MA, USA). Membranes were blocked with 
5% non-fat dry milk in TBS-Tween 20 followed by overnight incubations with a 
polyclonal primary rabbit anti-eGFP 1 :500; dilution; Al 1122; Invitrogen Molecular 
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Probes); monoclonal pnmary antibody to mouse a-tubulin (1 :2000; dilution; 
Ab11303 , Abeam plc) was used to normalize protein levels. Secondary horseradish 
peroxidase-conjugated antibodies ; anti-rabbit IgG (1 :5000; dilution; A4914; Sigma), 
anti-mouse IgG (1 :5000; dilution; A8924; Sigma) were incubated for 1hr and 
visualized by chemiluminescence (Amersham ECL plus, Baie d'Urfe QC, Canada) 
using the Carestream Software and Kodak Imager ( 4000MM Pro) (Kodak, 
Woodbridge CT, USA). 
2.3 Results: 
Overexpression of dsAA VS-RIP-eGFP is targeted to pancreatic f3-cells of the 
pancreas. 
Immunohistochemical analysis of pancreas sections collected from lean and obese 
mice infected with the control virus dsAA V8-RIPeGFP (8-eGFP-chow and P-eGFP-
HFD mice), showed eGFP immunofluorescence co-localized with insulin 
immunofluorescence (Fig. 2.2 A) in the islet as indicated by the green (eGFP) and red 
(insulin) overlay. GFP was found to be expressed in 74% of the insulin positive area in 
lean control islets whereas in obese islets eGFP was expressed in 24% of the insulin 
positive area (Fig. 2.2 B). 
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Fig 2.1: Immunohistochemical analysis of pancreatic sections from 
untreated mice revealed that the IHC technique employed with antibodies 
to insulin and eGFP produce expected results when performed on mouse 
islets. 
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Fig 2.2: A Immunohistochemical analysis revealed that infection of mice with 
dsAAV8-RIP-eGFP induces expression of eGFP in fi-cells of fi-eGFP-chow and 
fi-eGFP-HFD mice but not in fi-cells of untreated control mice. B (i) Estimate 
insulin positive area per region of interest in fi-eGFP-chow and fi-eGFP-HFD 
mice. (ii) The estimate percentage of eGFP immunoreactive area in total insulin 
positive area of islets from fi-eGFP-chow and fi-eGFP-HFD mice is 74% and 
24% respectively. Abbreviations: dsAAV8, double stranded adeno-associated 
virus serotype 8; RIP, rat insulin promotor; eGFP enhanced green fluorescent 
protein. Images taken at 20x magnification. Scale bar 50µm. 
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Overexpression of dsAA V8-RIP-eGFP is (}-cell specific and not expressed in 
peripheral tissues. 
To assess if eGFP protein expression was induced in peripheral tissues (liver, 
skeletal muscle, gonadal white adipose tissue, kidney, heart, liver and gonad) with 
viral infection (dsAAV-RIP-eGFP); we used Western blot analysis and 
immunohistochemistry. Using Western analysis, detection of eGFP in tissue extracts is 
expected to produce a 27kDa band. Analysis of Western blots revealed a 27kDa band 
in skeletal muscle, liver and gW AT protein extracts of both .8-eGFP-chow and .8-
PPARJ-chow mice (control) when incubated with a primary anti eGFP-antibody (Fig. 
2.3 A). Because the band was detected in both .8-eGFP-chow and .8-PPARJ-chow mice 
( control) we speculate this band appears due to non-specific binding of the antibody to 
a protein of similar size to eGFP, as eGFP is not an endogenous protein found in mice 
and thus the P-PPARJ-chow mice can serve as a negative control. Due to these 
inconclusive results, we utilized a second approach to assess eGFP expression in 
peripheral tissues to ensure the RIP was not inducing leaky expression. We employed 
immunohistochemical analysis of tissue sections (liver, gW AT and skeletal muscle) 
using the same eGFP antibody utilized for Western blot, as this would allow us to 
visualize the immunoreactivity in the context of the anatomy of the selected tissues. 
Immunohistochemical analysis of skeletal muscle, liver and gW AT revealed no eGFP 
immunoreactivity in any of the P-eGFP-chow and P-PPARJ-chow tissues listed above. 
Pancreatic sections from P-eGFP-chow mice were included as a positive control, 
which demonstrated the IHC protocol was robust (Fig. 2.3 B). Additionally, 
pancreatic sections of untreated mice were used as a negative control for the IHC 
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technique; it revealed no eGFP immunoreactivity to prove the antibodies were not 
binding non-specifically to viral proteins. These results conclude dsAA VS virus 
coupled with the RIP, specifically induces expression of the gene of interest 
specifically in pancreatic ~-cells and not in the peripheral tissues tested. 
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Fig 2.3: A. Western analysis of eGFP protein expression in non-pancreatic 
tissues. Non-specific binding of the eGFP primary Ab was observed in liver, 
skeletal muscle and gWAT tissue in both ,8-eGFP-chow mice and ,B-PPARc5-
chow mice. 30µg of protein per sample was loaded and run (see methods); 
except for gWAT in which 6.3 µg was used. a-tubulin immunoreactivity was 
utilized as a loading control. Abbreviations: dsAAV8, double stranded 
adeno-associated virus serotype 8; RIP, rat insulin promotor; eGFP, 
enhanced green fluorescent protein; -C, negative control (non-transfected 
MIN6 cells); +C. positive control, eGFP transfected MIN6 cells; gWAT, 
gonadal white adipose tissue. B. Immunohistochemical analysis of eGFP 
expression in non-pancreatic tissues. Staining revealed no eGFP expression 
in liver, skeletal muscle or gWAT tissue sections from ,8-eGFP-chow mice 
or ,B-PPARc5-chow mice. Images taken at 20x magnification. Scale bar 
50µm. 
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Overexpression of dsAA VS-RIP-PP ARJ is targeted to pancreatic P-cells. 
Immunohistochemical analysis of pancreas sections collected from lean and obese 
dsAAV8-RIP-PPARJ infected mice showed increased expression of PPARJ in 
pancreatic P-cells compared to P-cells of control mice (P-eGFP-chow and P-eGFP-
HFD mice) . As expected PPARJ immunofluorescence colocalized with nuclear 
staining (DAPI) in insulin positive cells as indicated by the red (PP ARJ), blue (nuclei) 
and green (insulin) overlay (Fig. 2.4) 
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Fig 2.4: Immunohistochemical analysis to detect PPARc5 overexpression in 
pancreatic .6-cells. Immunofluorescent staining revealed increased PPARc5 
imrnunoreactivity in pancreatic .6-cells of mice infected with dsAAV8-RIP-
PPARt5 (,6-PPARt5-chow and .B-PPARt5-HFD mice). PPAR8 immunofluorescence 
colocalized with nuclear staining (DAPI) in insulin positive cells as indicated by 
the red (PPARc5), blue (nuclei) and green (insulin) overlay. Abbreviations: 
dsAAV8 - double stranded adenoassociated virus serotype 8; RIP - rat insulin 
promotor; PPARt5 - Peroxisome proliferator activated receptor. Images taken at 
20x and 1 OOx magnification. Scale bar 50µm and 1 Oµm. 
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2.4 DISCUSSION 
As mentioned earlier in the introduction, transgenic induction of PP ARJ specifically 
in pancreatic P-cells was accomplished by utilizing a novel approach of viral mediated 
tissue specific gene delivery. This was achieved by a construct driving gene 
expression under the control of the rat insulin promoter in dsAA V8 adminstered via 
intraperitoneal injection (Wang, Zhu et al. 2006; Gaddy, Riedel et al. 2010). 
Administration of dsAA V8 via the intraperitoneal route provides a convenient and 
effective method for pancreatic gene delivery (Wang, Zhu et al. 2006). 
First we showed successful overexpression of eGFP in pancreatic P-cells of the islet, 
as lean and obese dsAAV8-RIP-eGFP infected control mice, showed eGFP 
immunofluorescence co-localized with insulin immunofluorescence (Fig. 2.2 A). 
These results are supported by previous studies from the Gray lab that showed adeno-
associated virus (dsAA V8-RIP-eGFP) specifically targets expression of eGFP to 
pancreatic P-cells in vivo with no expression observed in pancreatic a-cells and 
exocrine tissue. This result is further endorsed by finding of (Gaddy, Riedel et al. 
2010) who also confirmed eGFP protein expression induced by dsAA V8-RIP-eGFP 
localized to the pancreatic P-cell. In this study, eGFP was found to be expressed in 
74% of the insulin positive area in lean control (dsAA V8-RIP-eGFP-Chow) islets 
whereas in obese islets (dsAAV8-RIP-eGFP-HFD) eGFP was expressed in 24% of 
insulin positive area (Fig. 2.2 B). While, the same amount (5xl012 viral/genomes per 
mouse) of virus was injected to both lean and obese animals, the significant decrease 
in the percentage of infected P-cells in obese mice likely reflects the P-cell hyperplasia 
that occurs to compensate for the development of insulin resistance with obesity. 
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We next confirmed successful over expression of our experimental virus ( dsAA V8-
RIP-PP AR8) in pancreatic ~-cells of the islet. Similar to above, immunohistochemical 
analysis of pancreas sections collected from lean and obese dsAA V8-RIP-PPAR'5 
infected mice, showed increased PP ARc5 immunofluorescence in the nuclei 
( co localization with the nuclear stain DAPI) in insulin positive cells compared to /3-
cells from control dsAA V8-RIP-eGFP lean and obese mice (Fig. 2.4). 
Previous studies from the Gray lab and other colleagues (Gaddy, Riedel et al. 2010) 
have confirmed that overexpression of dsAA V8-RIP-eGFP in the pancreatic /J-cells 
did not affect body weight or overall carbohydrate metabolism and thus these studies 
were not repeated. 
Since it is known that dsAA V8 will target liver and skeletal muscle tissue in addition 
to the pancreas(Wang, Zhu et al. 2006; Wu, Asokan et al. 2006), we examined 
expression of eGFP protein in peripheral tissues (liver, skeletal muscle, kidney, gonad, 
gW AT and heart) of mice that received virus ( dsAA V8-RIP-eGFP). Western analysis 
of protein extracts isolated from tissues of dsAA V8-RIP-eGFP-chow mice revealed 
bands of an appropriate size (27kDa) in liver, skm and gW AT protein extracts. 
Inclusion of appropriate control samples concluded these bands were non-specific as 
they were also observed in skeletal muscle, gW AT and liver protein extracts from 
dsAA V8-RIP-PPARc5-chow (Fig. 2.3 A). Using a different approach, immuno-
histochemical analysis of skeletal muscle, g WAT and liver tissue samples of both 
dsAA V8-RIP-eGFP-chow and dsAA V8-RIP-PPARJ-chow mice were sectioned and 
stained for eGFP using immunohistochemistry. It was observed that eGFP was not 
expressed in skeletal muscle, gWAT and liver tissue in both dsAA V8-RIP-eGFP-chow 
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and dsAA V8-RIP-PPARJ -chow mice as the intensity of eGFP observed in dsAAV8-
RIP-eGFP-chow mice tissue sections was identical to the dsAAV8-RIP-PPARJ-chow 
mice tissue which was included as a negative control (Fig. 2.3 B). Based on our results 
and those of others (Gaddy, Riedel et al. 2010) we conclude that utilizing dsAAV8 for 
fl-cell specific gene delivery is an appropriate vector for developing and characterizing 
in vivo models of P-cell specific overexpression. In addition we showed specific 
expression in pancreatic P-cells with no leaky expression in tissues. 
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CHAPTER3 
Overexpression of PP ARo specifically in pancreatic P-cells impairs insulin 
secretion in lean and obese mice 
3.1 INTRODUCTION 
Persistently elevated nutrient supply such as glucose, amino acid, and fatty acids exerts 
detrimental effects on P-cell health. The condition of positive energy balance in obesity is 
associated with ectopic deposition of lipids in non-adipose tissue such as skeletal muscle, 
liver, heart and pancreatic P-cells (Assimacopoulos-Jeannet 2004). In the pancreas, this 
abnormal deposition of fat has detrimental effects (Newsholme, Keane et al. 2007). Both in-
vitro and in-vivo studies confirmed that chronic exposure to fatty acid leads to blunted glucose 
stimulated insulin secretion (Assimacopoulos-Jeannet 2004). 
Several mechanisms have been proposed for why chronic FF A exposure may impair P-cell 
function. Some of the suggested mechanisms include, chronic FF A may alter the gene 
expression of enzymes playing a critical role in glucose metabolism. Firstly, FF A exposure 
increases the activity of hexokinase, which shifts glucose responsiveness to lower glucose 
concentrations and contributes to the high insulin secretion at low glucose. Secondly, 
excessive amounts of FF A results in decreased insulin gene transcription leading to decreased 
insulin biosynthesis (Assimacopoulos-Jeannet 2004). 
Saturated FF As, derived mainly from the diet or lipolysis of fat depots, are strongly 
associated with insulin resistance. High plasma FF As inhibit insulin dependent glucose uptake 
in muscles, which leads to hyperglycemia. To cope with persistent hyperglycemia P-cells 
respond by increased insulin secretion to maintain normoglycemia, a process termed P-cell 
compensation. However if chronic exposure of FF A persists, ultimately P-cell failure occurs 
and results in impairment of insulin secretion (Prentki and Nolan 2006). LC-CoA activates 
ATP sensitive potassium (KA TP) channels and hyperpolarizes the P-cell, thus inhibiting its 
depolarization by glucose and leading to disruption of insulin exocytosis (van Herpen and 
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Schrauwen-Hinderling 2008). Finally, long-term exposure to FF A modifies the expression of 
UCP2, which is linked to a subsequent decrease in ATP production and disrupting of insulin 
secretion (van Herpen and Schrauwen-Hinderling 2008). 
Previous in vitro and in vivo studies suggest that prolonged exposure of P-cells or pancreatic 
islet to FF As results in increased triglyceride deposition within the P-cell. There is increasing 
evidence that the nature of the accumulated lipid plays a crucial role in the effect that it will 
have on P-cell function (Assimacopoulos-Jeannet 2004). For example, saturated palmitic acid 
rapidly induces P-cell apoptosis that is correlated with increased de novo synthesis of 
ceramides, a lipid species known to activate the apoptotic pathway in P-cells (Nolan, Leahy et 
al. 2006). On the other hand, unsaturated oleic .acid prevents apoptosis induced by palmitate, 
by upregulation of the anti-apoptotic protein bcl-2 (B-cell lymphoma 2) (Prentki and Nolan 
2006). 
Excessive lipid and glucose exposure induces oxidative stress in the P-cell. Saturated FF A, 
palmitate decreases the expression of malonyl-CoA production and subsequently increase 
camitine palmitoyl transferase I (CPT-1), the rate limiting enzyme in fatty acid oxidation 
(Assimacopoulos-Jeannet 2004), thus increasing the rate of P-oxidation in the P-cell. 
Oxidative stress is caused by the generation of reactive oxygen species (ROS) that exceeds 
reducing capacity of the cell. In P-cells it has been shown that short-term activation of ROS 
attenuates glucose stimulated insulin secretion, but excessive ROS impairs insulin secretion 
due to limited anti-oxidative defense mechanisms of P-cells leading to oxidative damage 
(Sharma and Alonso 2014). Consequences of oxidative stress include lipid peroxidation, 
oxidation of proteins, DNA damage and interference of reactive species in signal transduction 
(Sharma and Alonso 2014). 
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PPAR8 is the most abundant PPAR subtype in pancreatic P-cells at both the mRNA and 
protein level although its role in P-cell is not well understood and there is a limited body of 
literature available describing the role PP AR8 in P-cell. In vitro studies investigating the role 
of PP AR in this cell type have suggested PP AR8 to be the central regulator of genes involved 
in mitochondrial handling of fatty acid oxidation by causing an up regulation of genes 
involved in fatty acid oxidation (Wan, Jiang et al. 2010). Others have shown that the increase 
in fatty acid oxidation capacity of P-cells by PP AR8 potentiates glucose-stimulated insulin 
secretion (GSIS) in INS 1 cells and helps to alleviate the impairments of palmitate-induced 
lipotoxicity on glucose-stimulated insulin secretion (Wan, Jiang et al. 2010). In addition to its 
role involved in the lipid metabolism, recently, an in vivo study has shown PPAR8 plays a role 
in the cytoskeletal machinery required for the secretion of insulin in pancreatic P-cells 
(Iglesias, Barg et al. 2012). This study identifies a previously unrecognized role of PPAR8 in 
insulin secretion and suggests PP AR8 is required for normal insulin secretion. Iglesias et al. 
2012 showe that deletion of PP AR8 specifically in P-cells of the pancreas leads to enhanced 
insulin release during the second phase of glucose stimulated insulin secretion. Due to 
disorganization of the actin cytoskeleton (F-actin) and an altered Golgi apparatus, insulin 
granules were more easily accessible to plasma membrane (Iglesias, Barg et al. 2012). 
Based on the above in vitro studies in pancreatic p cells and the pro-oxidative role of 
PP AR8 in other organs such as skeletal muscle and liver, I hypothesized that overexpression 
of PP AR8 will induce oxidative gene expression and increase oxidative metabolism in 
pancreatic P-cells. In obesity, when islets are exposed to lipotoxic lipid accumulation, 
overexpression of PP AR8 may improve islet function and whole animal carbohydrate 
metabolism. Alternatively, if PPAR8 plays a fundamental role in suppressing insulin granule 
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exocytosis, as described above by Iglesias, Barg et al. 2012, enhancing PPARo activity in P-
cells may have detrimental effects on insulin secretion in the context of obesity. 
3.2 Material and method. 
Mice 
All animal studies were approved by the University of Northern British Columbia Animal 
Care and Use Committee (protocol number 2011-21). For this study, 8- week-old, male, 
C57Bl6 mice were purchased from Charles River Laboratories (Wilmington MA, USA) 
unless otherwise stated. Mice were maintained on a 12 hr light/dark cycle and received 
standard rodent chow diet (Rodent LabDiet, 5001, Leduc AB, Canada) ad libitum unless 
otherwise stated. Mice acclimatized in the animal facility for 1 week prior to experimental 
procedures. Body weight, 4 hr fasted blood glucose (OneTouch Ultra, Lifescan, Burnaby BC, 
Canada), overnight and random fed plasma insulin levels, oral glucose tolerance tests 
(OGTT) and insulin tolerance tests (ITT) were performed prior to viral injections to assess 
baseline carbohydrate metabolism. 
Double-stranded adeno-associated virus serotype 8. 
For this study dsAAV8 virus was prepared (dsAA V8-RIP-eGFP, dsAAV8-RIP-PPARo) by 
Children's Hospital of Philadelphia (CHOP) Research Vector Core Services (Philadelphia PA, 
USA). Virus construct was previously designed in Gray lab by Michael Nolan Craig, former 
graduate student. 
Pancreatic P-cell specific overexpression of eGFP and PPAR b in mice 
At 12-months of age, C57Bl6 mice were infected with dsAA V8-RIP-PPARo virus or a 
control virus dsAAV8-RIP-eGFP virus (5x1012 viral genomes), that has previously shown not 
to impact body weight, carbohydrate metabolism and P-cell insulin secretion (Hogh et al., 
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2013, Hogh et al., 2014) via intra-peritoneal injection. Four groups of mice were generated 
(n=8): P-eGFP-chow mice, P-PPAR8-chow mice, P-eGFP-HFD mice, P-PPAR8-HFD mice. 
Two days post injection two groups of mice (P-eGFP-HFD mice, P-PPAR8-HFD) were 
switched to a high fat diet (HFD) containing 45% kcal as fat. (D12451, Research Diets, New 
Brunswick NJ, USA) and the remaining two groups ( P-eGFP-chow mice, P-PPAR8-chow 
mice) received standard rodent chow diet (Rodent LabDiet, 5001; Leduc AB) ad libitum 
throughout the remainder of the experiment (25 weeks). Body weight was monitored weekly; 
4 hr fasted blood glucose was monitored biweekly and glucose tolerance, insulin secretion and 
insulin sensitivity were assessed monthly by OGTT, GSIS and ITT respectively. At the end of 
the 25wk study all animals were sacrificed. Tissues were collected and flash frozen or fixed 
in 4% paraformaldehyde for 48hrs and then stored in 70% EtOH. Whole pancreas sections (5 
µm) were prepared by WAXIT histological services (Vancouver BC, Canada). 
Insulin tolerance tests 
Mice were fasted for 4 hrs and given an ip injection of human synthetic insulin at 1.0U/kg 
(Novolin Ge, Toronto ON, Canada). Blood was sampled (1-2µ1) from the saphenous vein and 
blood glucose measured (mmol/L) at 0, 10, 20 30, 60, and 120 min post injection using 
handheld glucometer (OneTouch Ultra, Lifescan, Burnaby BC,Canada). 
Oral glucose tolerance and glucose-stimulated insulin secretion 
Mice were fasted for 16 hrs and given 2g/kg D-glucose by oral gavage. Plasma (15-20µ1) 
was sampled for insulin measurement at 0, 5, 10 and 120 minutes post glucose gavage from 
the saphenous vein and blood glucose (mmol/L) measured in 1-2µ1 blood at 0, 10, 20, 30, 60 
and 120 minutes post gavage using handheld glucometer (OneTouch Ultra, Lifescan, 
Burnaby BC, Canada) (Huynh et al. 2010). 
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Overnight fasted and re-fed plasma insulin levels 
Mice were fasted for 16 hrs and plasma was sampled from the saphenous vein by collecting 
blood heparinized capillary tubes (Fisher Scientific, Ottawa ON, Canada). Food was 
reintroduced for 2 hrs and plasma collected again. Blood glucose was determined using a 
handheld glucometer (OneTouch Ultra, Lifescan, Burnaby BC, Canada) and plasma insulin 
levels were assessed by ELISA (Ultrasensitive insulin ELISA assay, 80-INSMSU-EIO, 
ALPCO, Salem NH, USA). 
Immunohistochemistry: F-actin staining 
Whole mouse pancreas were fixed in 4% paraformaldehyde, embedded in paraffin and 
sectioned (5µm); n=5 per group (Wax-it Histology Services; Vancouver BC, Canada). All 
sections were de-paraffinized in xylene, rehydrated in ethanol (100%, 95%, and 70%) and 
rinsed in lxPBS. Permeabilize tissue with Triton-X (0.5%) for 10 and 30 min. Rinsed with 
lxPBS three times and separated sections on slides by using hydrophobic pen as each slide 
has two sections followed by application of Red fluorescent phalloidin conjugate solution (F-
actin staining kit ab112127) and incubated at room temperature for 90 min. Images were 
visualized under fluorescent light microscope (Olympus BX61) using Texas red filter and 
analyzed using Cell Sens Software (Olympus, Markham ON, Canada). 
Gene expression of SNARE protein in INS 1 cells 
Cell Culture 
INSl cells were cultured using RPMI-1640 Medium (R8758, Sigma, Oakville ON, Canada) 
at 37°C and 5% CO2. Culture media was supplemented with 10% fetal bovine serum (vol/vol) 
(F6178, Sigma, Oakville ON, Canada), lOmM HEPES (G7513, Sigma, Oakville ON, 
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Canada), 25µmol/L P-mercaptoethanol (M3148, Sigma, Oakville ON, Canada), and lOOU/mL 
penicillin-streptomycin (P4333, Sigma, Oakville ON, Canada). 
Transfection and PP AR overexpression 
INS 1 cells were cultured in 24-well plate with media containing no antibiotic. Cells were 
transfected with previously described dsAAV8-RIP-PPAR plasmid. In addition to dsAA V8-
RIP-PPAR8 plasmid, a dsAA V8-RIP-eGFP plasmid was designed to express eGFP in cells to 
serve as both a way of visualization transfection success and also as a control plasmid. The 
cells were transfected using 800ng of plasmid DNA, 1 µL of Lipofectamine® 2000 
(lnvitrogen, Burlington ON, Canada), and IOOµL of OPTI-MEM® (lnvitrogen, Burlington 
ON, Canada) per well, and incubated for 24 hours. Transfection efficiency of plasmid DNA 
was assessed by visualization of dsAAV8-RIP-eGFP transfected INSI cells using Olympus® 
FVIOOO Confocal Microscope (Olympus, Center Valley PA, USA). All wells were replaced 
with fresh media ( containing antibiotics) 16 hours post-transfection. 
Palmitate Treatment 
Upon successful transfection of plasmid DNA, cells were incubated for 24 hours in cell 
culture media containing 500µM palmitate. Palmitate media was prepared by dissolving 56mg 
palmitic acid (P5585, Sigma, Oakville ON, Canada) in lOmL of water containing lmL of IM 
NaOH. This solution was then heated to 70°C and 0.5mL combined with 1.65mL of 20% 
bovine serum albumin (BSA) (A6003, Sigma, Oakville ON, Canada) preheated to 37°C. 
Complexed BSA and palmitic acid (6:1 molar ratio) were then added to 17.85mL of cell 
culture media preheated to 3 7°C. 
Total RNA Extraction and cDNA Synthesis 
Total RNA was extracted from the cells 24 hours after palmitate treatment using the Qiagen 
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RNeasy Plus Mini Spin Kit according to the manufacturer's instruction (Qiagen, Valencia 
CA, USA). The extracted RNA samples were treated with Ambion TURBO-DNA Free™ 
(Life Technologies, Burlington ON, Canada) to remove genomic DNA. The concentration and 
purity (indicated by an A260/A280 ratio around 2.0) of the RNA were determined using the 
Nanodrop ND-1000 spectrophotometer (Table 1 ). RNA integrity was assessed by visualizing 
the presence of intact 18S and 28S ribosomal RNA bands on a 1.5% agarose gel containing 
0.5X TAE, 0.1% SYBR® Safe (Life Technologies, Burlington ON, Canada), and DEPC-
treated Milli-Q water (Figure 2). After the quality of the RNA had been confirmed, 500ng of 
RNA was taken from each sample and converted into cDNA using the iScript™ Reverse 
Transcription Supermix for RT-qPCR (Bio-Rad, Mississauga ON, Canada). 
Primer Design for qPCR 
Primers were designed towards overexpressed proteins: PPARcS, eGFP; several target genes: 
Syntaxinl, Syntaxin4, VAMP2 (vesicle associated membrane protein 2), CDC42 ( cell 
division control protein 42), PAKl (p21-activated protein kinase 1), SNAP23 (Synaptosomal-
associated protein 23), and SNAP25 (Synaptosomal-associated protein 25); and reference 
genes: B-actin, and TBP (TATA-binding protein). Primer sequences were either taken from 
those developed earlier by our lab, designed using Beacon Designer™ software and Primer-
BLAST from NCBI, or taken from the literature. The primers were designed to span exon-
intron boundaries, contain a G:C content ratio between 40-60%, have no secondary structure, 
avoid self-complementarity, and produce amplicon products approximately ?Ont to 150nt in 
length. Primers were ordered from and produced by Integrated DNA Technologies (IDT, 
Coralville IA, USA). 
Gene Expression Analysis 
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Optimization of Primers 
Primer optimization been done by Mr. Ahsen Chaudhry, a previous student in Dr. Gray's 
lab. 
General Protocol for qPCR 
Using the optimized and validated pnmers, qPCR (SYBR® Green chemistry) was 
performed on 1/10 dilutions of cDNA from three samples of both group in triplicate. No RT 
controls, which were produced from RNA samples loaded into cDNA synthesis reactions 
without reverse transcriptase, were run to ensure no genomic DNA contamination was present 
in the tested cDNA. In addition, No Template Controls (NTC) were included in each run to 
verify that there was no contamination in the qPCR reagents used. 
Reference Gene Evaluation 
Two reference genes, P-actin and TBP, were evaluated for stable expression within the 
experimental groups by geNorm analysis using the qBase+ software (Biogazelle, Zwijnaarde, 
Belgium). The measurement of stability is reported as an 'M' value for each evaluated 
reference gene, with values less than 1 deemed indicative of sufficient expression stability. 
The geNorm plot obtained demonstrated that the most stable reference genes examined were 
P-actin and TBP. 
Relative Quantification ofmRNA Gene Expression 
The data, including Ci values and standard deviations collected by the iQ5 software (Bio-
rad) for each of the genes were loaded into the qBase+ software and normalized to P-actin and 
TBP. This produced expression values for each of the three experimental replicates in both 
groups, which were then subjected to fold change analysis and normalized. Following this, the 
data was exported to the GraphPad Prism 6.0 software (GraphPad, La Jolla CA, USA), and 
50 
the mean and standard error for each experimental group was calculated. 
Statistical analysis 
Results are expressed as mean ± standard error of the mean. Analyses were performed using 
paired student's t-test and I-way ANOVA (significance between two groups), or 2-way 
ANOVAs (significance between groups over time) with Bonferoni Post tests using Graphpad 
Prism 6.0 software (La Jolla CA, USA). Significance was declared if p-values were less than 
0.05. *P<0.05, **P<0.01, ***P<0.001. 
3.3 RESULTS 
Effect of high fat feeding on obesity and carbohydrate metabolism in mice expressing the 
control plasmid ( dsAA V-RIP-eGFP) in pancreatic P-cells 
Two control groups of study, P-eGFP-chow and P-eGFP-HFD, were compared to observe 
the impact of pancreatic P-cell specific eGFP expression on carbohydrate metabolism in the 
pathophysiological condition of obesity. In comparison, diet induced obese control mice (P-
eGFP-HFD), fed HFD (45% kcal as fat) for 15 weeks, compared to lean control mice (P-
eGFP-chow) fed a standard chow diet for the same time period resulted in a significant 
increase in body weight (Fig 3.0 A) and insulin resistance (Fig 3.0 C) as expected. In this 
setting of insulin resistance and obesity, circulating glucose stimulated insulin levels (Fig 3.0 
E) were higher in obese control mice (P-eGFP-HFD) compared to lean control mice (P-eGFP-
chow) as expected. Additionally, circulating fed plasma insulin levels (Fig 3.0 F) in obese 
mice (P-GFP-HFD) were significantly higher compared to control lean (P-eGFP-chow) mice 
to compensate for the induction of insulin resistance induced in the obese state (Fig 3.0 D). 
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observed (1 U insulin/kg). Glucose tolerance D, at (Di) Baseline, (Dii) 2-months 
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Pancreatic fl-cell specific overexpression of PP ARo did not affect body weight and 
insulin sensitivity compared to lean (/J-PPARo-chow) and obese control mice (/J-PPARo-
HFD). 
Overexpression of PPAR8 specifically in pancreatic ,8-cells of lean (,B-PPAR8-chow) and 
obese mice (,B-PPAR8-HFD) did not affect body weight (Fig 3.1 A) (Fig. 3.2 A) and insulin 
sensitivity (Fig 3.1 C) (Fig 3.2 C) as compared to lean control (,8-eGFP-chow) and obese 
control (,8-eGFP-HFD) mice, overexpressing eGFP in pancreatic P-cells. 
1. Effect of pancreatic 13-cell-specific PPAR8 overexpression in lean mice (8-PPAR8-chow). 
Twelve week post infection, lean mice (,B-PPAR8-chow) overexpressing PPAR8 in ,8-cells 
showed a significant decrease in glucose stimulated insulin secretion as compared to the lean 
control mice (,8-eGFP-chow) (Fig 3.1 E). 
11. Effect of pancreatic 13-cell-specific PPAR8 overexpress10n m obese mice (8-PPAR8-
Obese mice (,B-PPAR8-HFD) overexpressing PPAR8 specifically in pancreatic ,8-cells 
showed a significant decrease in glucose stimulated insulin secretion 8 and 12 week post 
infection compared to obese control mice (,8-eGFP-HFD) (Fig 3.2 E). Additionally, 
circulating plasma insulin levels (Fig 3.2 F) in fed mice were significantly lower in,8-PPAR8-
HFD mice compared to control obese control (,8-eGFP-HFD) mice. 
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Fig 3 .1: Effect of pancreatic P-cell-specific PPARo overexpression in lean mice: Body 
weight A, 4 hr fasted blood glucose B, Insulin sensitivity C, at (Ci) Baseline, (Cii) 2-
months post-infection, (Ciii) 3-months post-infections was observed (1 U insulin/kg). 
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infections. F Fasted (16 h) and fed insulin levels in P-PPAR8-chow mice and P-eGFP-
chow mice. 
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Fig 3.2: Effect of pancreatic P-cell-specific PPARB overexpression in diet induced 
obese mice: Body weight A, 4 hr fasted blood glucose B, Insulin sensitivity C, at 
(Ci) Baseline, (Cii) 2-months post-infection, (Ciii) 3-months post-infections was 
observed (1 U insulin/kg) and Glucose tolerance (D) at (Di) Baseline, (Dii) 2-
months post-infection, (Diii) 3-months post-infections (2g D-glucose/kg). E P-
PPARB-HFD mic exhibit lower glucose stimulated insulin secretion compared to 
P-eGFP-HFD control mice in response to a glucose challenge (2g/kg) (Ei) 2-
months post-infection and, (Eii) 3-months post-infections. F Fasted (16 h) and fed 
insulin levels in P-PPARB-HFD mice and P-eGFP-HFD mice. 
58 
Impact of pancreatic p-cell specific overexpression of PP AR5 on glucose tolerance of 
mice 
Overall, significantly decreased circulating insulin levels were observed in both lean (/J-
PP AR8-chow) and obese mice (/J-PPAR8-HFD) overexpressing PPAR8 in pancreatic ,B-cells 
compared to respective lean (/J-eGFP-chow) and obese (/J-eGFP-HFD) controls. Surprisingly, 
decrease in insulin levels is not associated with impairment in glucose tolerance. 
Interestingly, lean mice (/J-PPAR8-chow) showed an improved glucose tolerance (Fig 3.1 
D) as compared to lean (/J-eGFP-chow) control mice and obese PPAR8 mice (/J-PPAR8-HFD) 
showed the same glucose tolerance like their respective obese controls (Fig 3.2 D). 
When insulin levels of both lean (/J-PPAR8-chow) and obese mice (/J-PPAR8-HFD) 
overexpressing PP AR8 in pancreatic ,B-cells were compared, higher plasma insulin was 
observed in obese mice (P-PPAR8-HFD) compared to lean mice (/J-PPAR8-chow). This 
increase in insulin secretion that occurs in response to the obese state due to P-cell 
compensation was not as pronounced as the increase seen between the control animals (Fig 
3.0 E). 
F-actin staining of mice pancreatic sections with phalloidin dye 
Immunohistochemical analysis of pancreatic sections of saline injected mice showed no F-
actin staining in P-cells. However, the exocrine part of the pancreas showed 
immunofluorescence that could be seen in both 20x and 40x magnification (Fig 4.0 A). 
F-actin staining of mice pancreatic sections exposed to 0.5% Triton-X for 10 and 30 
minutes 
Immunohistochemical analysis of pancreatic sections treated with 0.5% triton-x 100 for 10 
and 30 min to increase P-cell membrane permeability, before phalloidin staining showed no F-
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actin staining in ~-cells. However, it showed immunofluorescence in the exocrine part of the 
pancreas as described above (Fig 4.0 B) 
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Saline mice no 
phalloidin dye 
Saline mice with 
phalloidin dye 
Saline mice no 
phalloidin dye treated 
with triton-x100 1 Omin 
Saline mice with 
phalloidin dye treated 
with triton-x100 10min 
Saline mice no 
phalloidin dye treated 
with triton-x100 30min 
Saline mice with 
phalloidin dye treated 
with triton-x100 30min 
DAPI F-actin 
DAPI F-actin 
Fig 4.0 Immunohistochemical analysis to visualize F-actin staining in pancreatic P-
cells of saline infected mice. A. Phalloidin dye treated pancreatic section of saline 
infected mice showed no F-actin staining in P-cells. Control of the technique i.e 
pancreatic section of saline injected mice with no Phalloidin dye showed no 
immunofluorescence. B. Pancreatic sections treated with 0.5% triton-x 100 for 10 
and 30 minutes also showed no immunofluorescence in P-cells. 
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Successful overexpression of PPARo mRNA in INS-1 transfected cells with RIP-PPARo 
and gene expression analysis of important insulin secretion mediators. 
Overexpression of PPAR8 induced by transfection of the RIP-dsAA V8-PPAR8 plasmid was 
assessed in INS-1 cells using real-time PCR. INS-I cells transfected with RIP-dsAA V8-
PPAR8 had significantly higher PPAR8 mRNA expression compared to cells overexpressing 
RIP-dsAA V8-eGFP plasmid. Gene expression analysis of INS-1 cells transfected with RIP-
dsAA V8-PPAR8 plasmid and treated with 500mM palmitate showed significant 
downregulation of snap25 mRNA as compared to cells transfected with RIP-dsAA V8-eGFP 
and treated with 500mM palmitate. No change in gene expression of V AMP2 (vesicle 
associated membrane. protein 2), CDC42 (cell division control protein 42), PAKl (p21-
activated protein kinase 1) and SNAP23 (Synaptosomal-associated protein 2) was observed as 
compared to control (Fig 5.0) 
62 
200 - INS-1 eGFP+500mM Palmltate 
c:::J INS-1 PPAR-o+ 500mM Palmltate 
180 
C 
.Q a.. 160 
en cc 
~f--s~ 140 
<( :§ 
z~ 
0::: c6.. 120 
E o 
C .... 
-~ °fil 100 
c~ 20 co co • uE 
'.§ ~ 1.5 
u. 
1.0 
0.5 
*** r--, 
* .-, 
Fig 5.0: Overexpression of PPAR8 in INS-1 cells and expression of insulin 
exocytosis mediators: Overexpression of INS-1 cells with PPAR6 and treatment 
with palmitate downregulate expression of Snap23mRNA while no change in 
expression of other mediators. Abbreviations: PPAR8 - peroxisome proliferator-
activated receptor alpha; INS-1 rat insulinoma cell line; eGFP - enhanced green 
fluorescent protein, VAMP2 - vesicle associated membrane protein 2, CDC42 -
cell division control protein 42, PAKl- p21-activated protein kinase 1, SNAP23 -
Synaptosomal-associated protein 23, and SNAP25 -Synaptosomal-associated 
protein 25. 
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3.4 DISCUSSION 
Ligands for peroxisome proliferator-activated receptor o (PPARo) have the potential for 
treating diabetes and obesity due to their ability to improve insulin sensitivity by increasing 
fatty acid catabolism in skeletal muscle (Barish, Narkar et al. 2006). However, the direct 
effect of PP ARo agonism in pancreatic P-cells is not well known. Its role needs to be further 
elucidated at the organ level before considering it for the treatment of metabolic disease. 
Previous in vitro studies suggest, that an increase in fatty acid oxidative capacity of P-cells 
induced by PP ARo overexpression potentiates glucose-stimulated insulin secretion and helps 
to alleviate the impairment of palmitate-induced lipotoxicity on glucose-stimulated insulin 
secretion. Hence the in-vitro studies suggest PP ARo activation in P-cells plays a protective 
role against obesity-induced P-cell failure (Ravnskjaer, Boergesen et al. 2005; Ravnskjaer, 
Frigerio et al. 2010). In contrast, conditional knockout of PPARo in pancreatic P-cells in-vivo, 
revealed an unexpectedly broad repressive role for PP ARo on pancreatic P-cell proliferation 
and function. Phenotypic characterization of mice lacking PP ARo in pancreatic P-cells 
identified the role of PP ARo to inhibit insulin secretion due to disorganization of the actin 
cytoskeleton and an altered Golgi apparatus (Iglesias, Barg et al. 2012). Due to these 
contrasting studies the metabolic role of PPARo in pancreatic P-cells is still unclear in the 
literature and should be further investigated. The aim of this study was to further explore the 
role of PPARo in pancreatic P-cells. This was carried out using an in vivo model in which 
PP ARo was overexpressed specifically in pancreatic P-cells of lean and obese mice. 
It has been shown that in vivo overexpression of PP ARo specifically in pancreatic P-cells 
significantly impaired glucose stimulated insulin secretion in both lean (8-PPARo-chow) and 
obese (8-PPARo-HFD) mice compared to lean (8-eGFP-chow) and obese (8-eGFP-HFD) 
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control mice. No change in body weight or insulin sensitivity was observed in lean (,B-PPAR8-
chow) and obese (,B-PPAR8-HFD) mice overexpressing PPAR8 compared to lean (,8-eGFP-
chow) and obese (,8-eGFP-HFD) controls as expected. It has been investigated that PPAR8 
can protect against obesity by depleting dyslipidemia and insulin resistance via effects in 
skeletal muscle, adipose tissue, (Grant D. Barish et al, 2006) and liver (Iglesias, Barg et al. 
2012). To avoid indirect effect of PPAR8 activation on carbohydrate metabolism, and to 
assess its sole involvement in P-cells, mice were generated that overexpressed PP AR8 
specifically in pancreatic P-cells. 
Despite impaim1ent of insulin secretion in lean (,8-PP AR8-chow) and obese (P-PPAR8-HFD) 
mice overexpressing PP AR8, an unexpected and unexplained improvement in glucose 
tolerance was observed. As expected, higher plasma insulin was observed in obese mice (P-
PP AR8-HFD) compared to lean mice (,B-PPAR8-chow). In obesity-associated insulin 
resistance, pancreatic P-cells responded by secreting more insulin to overcome the insulin 
resistance, a process known as P-cell compensation (Marc Prentki et al. 2006). P-cell 
compensation seen in P-PPAR8-HFD mice was not as pronounced as the increase seen in 
control obese mice (,8-eGFP-HFD). The decrease in insulin secretion with PPAR8 
overexpression in both lean and obese mice provides important data to support a fundamental 
role of PPAR8 in the insulin secretory mechanism. This data is compatible with the finding 
that PP AR8 null islets exhibit enhanced insulin release specifically in the second phase of 
glucose stimulated insulin secretion (Iglesias, Barg et al. 2012). This enhancement in insulin 
secretion was related to disorganization of F-actin cytoskeleton, which makes easy access of 
insulin granules to periphery (Iglesias, Barg et al. 2012). Hence, to assess the impact of 
PP AR8 overexpression on F-actin organization in P-cells of our model, it was decided to 
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investigate F-actin in pancreatic sections of lean and obese mice. Unfortunately, due to some 
technical difficulties, staining of pancreatic sections with phalloidin dye was unsuccessful. 
Alternatively, it was decided to look at the gene expression profile of important insulin 
secretory mediators in a pancreatic P-cell line overexpressing PP AR8 to assess if PP AR8 can 
directly affect gene transcription of important insulin secretory mediators. The gene 
expression profile revealed a significant downregulation of Snap25 mRNA, an important 
SNARE protein involved in the fusion of synaptic insulin vesicles with the presynaptic plasma 
membrane that leads to insulin secretion (Sadoul, Lang et al. 1995; Iglesias, Barg et al. 2012). 
This study also looked at mRNA level of important mediators involved in insulin secretory 
machinery and also found significant downregulation of important the SNARE protein 
Snap25 as compared to the control. Downregulation of this important mediator in both PP AR8 
null and PP AR8 overexpressing mice show a potential interaction with PP AR8. However, 
these results are still inconclusive until the protein level of Snap25 is checked. 
To further confirm the mechanistic role of PP AR8 in pancreatic P-cells additional experiments 
need to be performed. 
Future directions for this project include: 
1. Overcome technical difficulties of F-actin staining. Stain pancreatic sections with 
phalloidin dye to see the impact of PPAR8 overexpression on F-actin organization in P-cells. 
2. Check the protein expression levels of important insulin secretory mediators to determine 
conclusively if PP AR8 can impact the protein level of these mediators. 
3. Check the protein activity (protein/total protein) levels of important mediators of insulin 
secretion such as Cdc42 and PAKl. 
In conclusion, the main findings of this chapter are: 
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1. Overexpressions of dsAAV8-RIP-PPAR8 specifically m pancreatic P-cells result m 
impairment of insulin secretion both in lean and obese mice. 
2. Overexpressions of dsAAV8-RIP-PPAR8 in pancreatic P-cells improve glucose tolerance 
in both lean and obese mice. 
The data generated in this study where PP AR8 was overexpressed in pancreatic P-cells, along 
with the data published in (Iglesias, Barg et al. 2012) has highlighted a fundamental role of 
PP AR8 in the insulin secretory mechanism of pancreatic P-cells. In future studies the role of 
PP AR8 in pancreatic P-cells should be considered when PP AR8 agoinst are proposed for 
therapeutic intervention to treat diabetes. 
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CHAPTER4 
Concluding Remarks 
4.1 Concluding Remarks 
It has been well established that a major cause of P-cell dysfunction in obesity-induced 
T2D is lipotoxicity (Prentki and Nolan 2006) (Poitout 2008; Poitout and Robertson 
2008). The hypothesis of this project was to understand if the pro-oxidative potential of 
PPAR8 can protect pancreatic P-cell dysfunction from obesity-induced lipotoxicity. The 
idea was based on in-vitro studies conducted by Ravnskjaer, K. , et al 2010 and Wan, J., et 
al 2010, demonstrating the potential of PP AR8 to alleviate the impairment of palmitate-
induced lipotoxicity on glucose-stimulated insulin secretion in INS-1 E and HIT-T 15 cells 
(P-cell lines) (Ravnskjaer, Frigerio et al. 2010; Wan, Jiang et al. 2010). Despite this 
information, our in-vivo model of pancreatic P-cell specific PPAR8 overexpression 
showed a primary phenotype of impaired insulin secretion both in lean (P-PPAR8-chow) 
and obese (P-PPAR8-HFD) mice compared to lean (P-eGFP-chow) and obese (P-eGFP-
HFD) control mice. Impairment of insulin secretion in both the lean (P-PPAR8-chow) 
and obese (P-PPAR8-HFD) settings distinctly recognizes involvement of PPAR8 in 
fundamental processes of insulin secretion. This finding along with a study whereby 
PPAR8 is genetically ablated from adult pancreatic P-cells (Iglesias, Barg et al. 2012) are 
the only two in vivo studies that pinpoint a role for PP ARO in insulin secretory 
mechanisms. Further studies exploring the pro-oxidative protective potential of PPAR8 in 
pancreatic P-cells may not be worthwhile to study due to PP AR8 involvement in 
impairment of insulin secretion, an important finding of our study that is further endorsed 
by in vivo P-cell specific PPAR8 knockout model study (Iglesias, Barg et al. 2012). Based 
on this finding, PPAR8 activation is not a valuable strategy for therapeutic treatment of 
obesity-induced T2D, as it would result in worsening the condition due to further 
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impairment in insulin secretion. 
Results from my thesis suggest that PP AR8 primary role in pancreatic P-cells is on 
insulin secretion and future studies should be pursued to better understand how PP AR8 
mediates insulin secretory mechanisms. 
4.2 Key Finding 
~ The key finding of this study is that PP AR8 overexpression specifically in pancreatic P-
cells results in impairment of insulin secretion in lean (P-PPAR8-chow) and obese (P-
PPAR8-HFD) mice compared to controls. Impairment in both lean (P-PPAR8-chow) and 
obese (P-PPAR8-HFD) mice suggest a fundamental role for PPAR8 as mediator of 
insulin secretion from pancreatic P-cells. 
~ Surprisingly, in spite of the observed impairment in insulin secretion and unchanged 
insulin sensitivity in lean (P-PPAR8-chow) and obese mice (P-PPAR8-HFD), 
overexpressing PP AR8 specifically in pancreatic P-cells has improved glucose tolerance 
compared to lean (P-eGFP-chow) and obese (P-eGFP-HFD) control mice. 
4.3 Future Direction 
The focus of this thesis has been to examine the role of PP AR8 specifically in pancreatic 
picell function in both the lean (P-PPAR8-chow) and obese (P-PPAR8-HFD) setting_,_ 
There are several avenues that need to be further explored to fully investigate the in vivo 
impact of PP AR8 overexpression in pancreatic P-cells in regulating insulin secretion. 
First and foremost is to discern the impact of PPAR8 activation on F-actin organization 
by immunofluorescent staining using antibodies instead of the conventional method of F-
actin visualization with Phalloidin dye. This would allow us to determine if PP AR8 
70 
overexpression in pancreatic P-cells cause impairment in insulin secretion by increasing 
the density of the F-actin network, thereby impairing access of insulin granules to the 
plasma membrane. This finding is based on published data by Iglesias et al, 2012 that 
sh owes removal of PP ARc5 from the ,B-cell enhanced second phase insulin secretion due 
to disassembly of F-actin network, allowing uninhibited insulin granule access to plasma 
membrane (Iglesias, Barg et al. 2012). 
A significant reduction of Snap 23 mRNA was observed during gene express10n 
analysis of SNARE protein genes in dsAA V8-RIP-PPAR8 transfected cells compared to 
dsAA V8-RIP-eGFP transfected INS-1 cells. As, Snap 23 is involved in fusion of insulin 
granules to the plasma membrane, its dowmegulation could result in reduced fusion of 
insulin granules and ultimately contribute to the impairment in insulin secretion observed 
with PPAR8 overexpression. J Iglesias. , et al 2012 also revealed Snap 23 mRNA down 
regulation in P-cell specific PP AR8 knockout model. Further evidence to confirm if Snap 
23 is a target gene of PP AR8 warrants measurement of Snap 23 protein levels in 
pancreatic P-cells overexpressing PP AR8 by performing a western blot. Also, it would be 
valuable to check the protein levels and protein activity of other insulin exocytosis 
mediators highlighted in Fig 6. Protein activity of mediators would be checked by 
measuring the level of the phosphorylated form of the protein compared to the total 
amount of protein by overexpressing PPAR8 using a western blot with phospho-
antibodies. 
To discern which phase (1 st or 2nd) of insulin secretion is affected, glucose stimulated 
insulin secretion from islets overexpressing PPAR8 by transfection with dsAA V8-RIP-
PPAR8 will be studied ex-vivo. If overexpression of PPAR8 specifically in pancreatic P-
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cells impairs insulin secretion due to a dense F-actin network, the expected result would 
be impairment in the 2nd phase of insulin secretion. This expected finding would correlate 
with results from the P-cell specific PP AR8 knockout study in which they saw 
accelerated 2nd phase of insulin secretion due to disorganization in F-actin network 
(Iglesias, Barg et al. 2012). 
In this study an unexpected finding of improved glucose tolerance was observed in both 
lean (P-PPAR8-chow) and obese (P-PPAR8-HFD) mice despite impairment in insulin 
secretion and unchanged insulin sensitivity. To explore this unexpected finding future 
experiment need to be conducted. Hyperinsulinemic clamps could be used to assess 
insulin sensitivity and glucose utilization of specific organs. In chapter 3 of this thesis an 
insulin tolerance test was used to asses whole animal insulin sensitivity, which is not as 
sensitive as hyperinsulinemic euglycemic clamps at assessing insulin sensitivity. 
Additionally, hyperinsulinemic euglycemic clamps allow measurement of tissue specific 
insulin sensitivity, compared to insulin tolerance test that report insulin sensitivity in 
terms of the whole animal. Additionally, the hyperinsulinemic clamp allows glucose 
utilization of specific tissues to be measured at the organ level. 
72 
3. Protein activity levels 
of highlighted 
mediators 
2. Protein levels of 
highlighted mediators 
1. F-actin staining 
Glucose 
• 
Iglesias. J et al 2012 
proposed that KO of 
PPAR8 increased 
filamentous actin (F-
actin) disassembly 
4. First and Second 
phase of insulin 
secretion in islets 
overexpressing PPAR8 
ex VIVO 
F-actin Remodeling 
Syntaxin 4 
~ 
~ Insulin secretion 
Fig 6.0 Pathways impinging specifically on glucose-mediated F-actin 
remodeling in the ~-cell and PPAR8 involvement in the pathway. Future 
direction are highlighted based on already known role of PPAR8 and key finding 
of my study (Recreated from Kalwat and Thurmond 2013). 
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4.4 Significance 
P-cell specific overexpression of PP AR8 results in impairment of insulin secretion in 
mouse. This is the second study that provides in vivo evidence to support a role of PP AR8 
in mechanism of insulin secretion in scientific literature (Iglesias, Barg et al. 2012), and 
the work demonstrated in this thesis is the first to show this effect in both the lean (P-
PP AR8-chow) and obese (P-PPAR8-HFD) settings. This study gives new insight into the 
functional role of PP AR8 in the P-cell, suggesting it plays an important role in insulin 
secretion as well as being involved in fatty acid oxidation based on in-vitro studies in P-
cells and its known role in oxidation from studies performed in other organs (Ravnskjaer, 
Frigerio et al. 2010; Wan, Jiang et al. 2010). 
This work allows the proposal of repressive role of PP AR8 in secretion of insulin from 
insulin granules. It is proposed that PP AR8 could be involved in regulating this process in 
several ways (as shown in Fig 6). As obesity-induced T2D is characterized by insulin 
resistance and inadequate insulin secretion PP AR8 activation in T2D would intensify 
impairment in insulin secretion due to its involvement in the insulin granule secretory 
process, which would result in further aggravation of the condition. As such, future 
consideration of PPAR8 activation as a therapeutic target to alleviate obesity-induced 
lipotoxicity in pancreatic P-cells should be approached with caution, as this study 
highlights that the PPAR8 role is not limited to regulation of lipid metabolism and may 
also induce a break in the insulin secretory process. 
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